Clinical Trials - INSM

NCT IDTitleStatusPhasesStart DateCompletion DatePrimary Completion Date
NCT07179380Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)NOT_YET_RECRUITINGPHASE32025-10-012028-12-302028-12-30
NCT07102316A Study to Assess the Relative Bioavailability After a Single Inhalation Administration of Treprostinil Palmitil Inhalation Powder (TPIP) Formulation 2 (F2) to TPIP Formulation 3 (F3) in Healthy ParticipantsRECRUITINGPHASE12025-08-192025-11-092025-11-02
NCT06817382A Study to Investigate the Safety and Biodistribution of a Single Intrathecal (IT) Injection of INS1201 in Ambulatory Males With Duchenne Muscular Dystrophy (DMD)RECRUITINGPHASE12025-07-222028-03-312028-01-31
NCT06685835A Study of the Efficacy and Safety of Brensocatib in Adults With Moderate to Severe Hidradenitis Suppurativa (HS)RECRUITINGPHASE22024-12-162027-01-282026-05-22
NCT06344728A Study to Assess the Relative Bioavailability of Brensocatib Pediatric Oral Solution to Oral Tablets in Healthy ParticipantsCOMPLETEDPHASE12024-04-302024-05-242024-05-24
NCT06178783A Study of the Palatability and Acceptability of Different Brensocatib Oral Liquid Formulations in Healthy ParticipantsCOMPLETEDPHASE12023-12-272024-01-042024-01-04
NCT06013241A Study of the Efficacy and Safety of Brensocatib in Participants With Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)ACTIVE_NOT_RECRUITINGPHASE22023-10-302025-09-252025-08-29
NCT05965570A Study to Investigate Effect of Clarithromycin, a Strong CYP3A4 Inhibitor, on Brensocatib Pharmacokinetics in Healthy ParticipantsCOMPLETEDPHASE12023-07-282023-09-222023-09-22
NCT05649722An Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)ACTIVE_NOT_RECRUITINGPHASE2, PHASE32023-05-112026-03-142026-03-14
NCT05826574A Study to Assess Pharmacokinetics (PK) of Brensocatib Alone and With Multiple Doses of Rifampin or Esomeprozole in Healthy ParticipantsCOMPLETEDPHASE12023-05-102023-07-162023-07-16
NCT05649748An Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Arterial Hypertension (PAH)ACTIVE_NOT_RECRUITINGPHASE2, PHASE32023-03-072026-12-312026-12-31
NCT05176951A Study to Evaluate the Safety and Tolerability of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Hypertension Associated With Interstitial Lung DiseaseCOMPLETEDPHASE22022-12-222024-03-142024-03-14
NCT05517525A Study to Evaluate the Pharmacokinetics (PK) and Safety of a Single Dose of Brensocatib in Participants With Normal Hepatic Function and Participants With Hepatic ImpairmentCOMPLETEDPHASE12022-10-042023-06-012023-06-01
NCT05147805A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Arterial HypertensionCOMPLETEDPHASE22022-08-242025-03-272025-03-27
NCT05355935A Study to Investigate the Effects of Brensocatib on QT Interval in Healthy ParticipantsCOMPLETEDPHASE12022-04-272022-10-072022-10-07
NCT04791514A Study of Treprostinil Palmitil Inhalation Powder (TPIP) In Pulmonary Arterial Hypertension (PAH)TERMINATEDPHASE22022-03-292022-08-262022-08-26
NCT05090904A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Brensocatib Tablets in Adults With Cystic FibrosisCOMPLETEDPHASE22021-11-302022-11-012022-11-01
NCT05652257A Study of the Absorption, Metabolism, and Excretion of [14C]-Brensocatib Following a Single Oral Administration in Healthy Male ParticipantsCOMPLETEDPHASE12021-08-132021-09-142021-09-14
NCT05673603A Study of Brensocatib Following a Single Oral Administration in Participants With or Without Renal ImpairmentCOMPLETEDPHASE12021-07-202023-02-142023-02-14
NCT04677569Study to Evaluate ALIS (Amikacin Liposome Inhalation Suspension) in Participants With Nontuberculous Mycobacterial Lung Infection Caused by Mycobacterium Avium ComplexACTIVE_NOT_RECRUITINGPHASE32021-04-012026-01-152025-11-15
NCT04677543Validation of Patient Reported Outcome Measures in Participants With Nontuberculous Mycobacterial Lung Infection Caused by Mycobacterium Avium ComplexCOMPLETEDPHASE32020-12-222023-05-092023-05-09
NCT04594369A Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib in Participants With Non-Cystic Fibrosis BronchiectasisCOMPLETEDPHASE32020-12-012024-10-282024-10-28
NCT06091579A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder (TPIP) in Healthy ParticipantsCOMPLETEDPHASE12020-09-172021-01-122021-01-12
NCT05927597A Study of the Safety, Pharmacokinetics, and Pharmacodynamics of INS1007 in Healthy Japanese and Caucasian ParticipantsCOMPLETEDPHASE12019-01-092019-08-012019-08-01
NCT03218917Assessment of INS1007 in Participants With Non-Cystic Fibrosis BronchiectasisCOMPLETEDPHASE22017-10-312019-12-122019-12-12
NCT02628600Open-label Safety Extension Study Assessing Safety and Tolerability of LAI in Patients Who Participated in Study INS-212COMPLETEDPHASE32016-02-052018-10-172018-10-17
NCT06193031A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of C16TR for Inhalation With Tyvaso® Cohort in Healthy ParticipantsCOMPLETEDPHASE12015-11-172015-12-182015-12-18
NCT02344004Study to Evaluate Efficacy of LAI When Added to Multi-drug Regimen Compared to Multi-drug Regimen AloneCOMPLETEDPHASE32015-05-272019-04-032018-07-03
NCT01316276Extension Study of Liposomal Amikacin for Inhalation in Cystic Fibrosis (CF) Patients With Chronic Pseudomonas Aeruginosa (Pa) InfectionCOMPLETEDPHASE32012-10-052015-07-162015-07-16
NCT01315236Liposomal Amikacin for Inhalation (LAI) for Nontuberculous MycobacteriaCOMPLETEDPHASE22012-04-192015-06-182014-08-18
NCT01315678Study to Evaluate Arikayce™ in CF Patients With Chronic Pseudomonas Aeruginosa InfectionsCOMPLETEDPHASE32012-02-292013-09-182013-06
NCT03905642Study of Dose Escalation of Liposomal Amikacin for Inhalation (ARIKAYCE™) - Extension PhaseCOMPLETEDPHASE22009-01-082010-11-022010-11-02
NCT00775138Safety and Tolerability Study of 2 Dose Level of Arikayce™ in Patients With Bronchiectasis and Chronic Infection Due to Pseudomonas Aeruginosa.COMPLETEDPHASE22008-06-242009-05-112009-05-11
NCT00558844Safety/Tolerability Study of Arikayce™ in Cystic Fibrosis Patients With Chronic Infection Due to Pseudomonas AeruginosaCOMPLETEDPHASE1, PHASE22008-012009-062009-06
NCT00577577Safety and Efficacy Study of Recombinant Human Insulin-Like Growth Factor-I/Recombinant Human Insulin-Like Growth Factor Binding Protein-3 (rhIGF-I/rhIGFBP-3) In Myotonic Dystrophy Type 1COMPLETEDPHASE22007-122008-12-292008-12-29
NCT00777296Multidose Safety and Tolerability Study of Dose Escalation of Liposomal Amikacin for Inhalation (ARIKACE™)COMPLETEDPHASE1, PHASE22007-02-222008-02-272008-02-27
NCT00102531Inhalation SLIT Cisplatin (Liposomal) for the Treatment of Osteosarcoma Metastatic to the LungCOMPLETEDPHASE1, PHASE22005-01-122008-03-172008-03
NCT05999942A Study to Investigate Lung Deposition of Inhaled Amikacin-loaded Liposomes in Healthy Male ParticipantsCOMPLETEDPHASE12004-06-022004-06-292004-06-29
NCT06238856Single Dose Escalation Study of TR02 (Sustained Lipid Inhalation Technology [SLIT™] Amikacin) in Participants With Cystic Fibrosis (CF) Having Chronic Infections of Pseudomonas AeruginosaCOMPLETEDPHASE12004-05-122005-02-082005-02-08
NCT01315691Study to Evaluate Arikace™ in CF Patients With Chronic Infection Due to Pseudomonas AeruginosaWITHDRAWNPHASE3
NCT00368173IGF-I/IGFBP-3 Therapy in Children and Adolescents With Growth Hormone Insenitivity Syndrome (GHIS) Such as Laron SyndromeCOMPLETEDPHASE2, PHASE3
NCT00351221Research Study Using Recombinant Human Insulin-Like Growth Factor-1/Recombinant Human Insulin-Like Growth Factor Binding Protein-3 for Children With Noonan SyndromeTERMINATEDPHASE2